Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.16967442870619853 | N/A |
Market Cap | $49.15M | N/A |
Shares Outstanding | 289.68M | 20.22% |
Employees | 0 | N/A |
Shareholder Equity | 53.68M | 26.86% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.95 | N/A |
P/S Ratio | 1548.75 | N/A |
P/B Ratio | 0.92 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.6563 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $31.74K | N/A |
Earnings | -$35.23M | N/A |
EPS | -0.1792 | N/A |
Earnings Yield | -1.06 | N/A |
Gross Margin | 0.5974 | N/A |
Operating Margin | -1.28K | N/A |
Net income margin | -1.11K | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $45.52M | N/A |
Total Debt | $231.89K | N/A |
Cash on Hand | $38.23M | N/A |
Debt to Equity | 0.1693 | 26.03% |
Cash to Debt | $164.88 | 156.27% |
Current Ratio | $4.89 | -18.81% |